Pharmacology & Therapeutics

Pharmacology & Therapeutics

药理学与治疗学

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Pharmacology & Therapeutics》是由Elsevier Inc.出版社于1979年创办的英文国际期刊(ISSN: 0163-7258,E-ISSN: 1879-016X),该期刊长期致力于药学领域的创新研究,主要研究方向为医学-药学。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA未开放获取模式(OA占比0.1800...%),以发表药学领域等方向的原创性研究为核心(研究类文章占比0.00%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在147篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Pharmacology & Therapeutics审稿周期约为 偏慢,4-8周 约15.8周。该刊近年未被列入国际预警名单,年发文量约147篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 147 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 8 / 354

97.9%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 16 / 354

95.62%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:23 SJR:3.15 SNIP:2.467
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q1 2 / 272

99%

大类:Medicine 小类:Pharmacology Q1 7 / 313

97%

期刊发文

  • Detailed curriculum vitae of HER2-targeted therapy

    Author: Zhang, Xiao-Nan; Gao, Ya; Zhang, Xi-Ya; Guo, Ning-Jie; Hou, Wen-Qing; Wang, Shu-Wu; Zheng, Yi-Chao; Wang, Ning; Liu, Hong -Min; Wang, Bo

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 245, Issue , pp. -. DOI: 10.1016/j.pharmthera.2023.108417

  • Neutrophil extracellular traps: A novel target for the treatment of stroke

    Author: Zhao, Ziyuan; Pan, Zirong; Zhang, Sen; Ma, Guodong; Zhang, Wen; Song, Junke; Wang, Yuehua; Kong, Linglei; Du, Guanhua

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 241, Issue , pp. -. DOI: 10.1016/j.pharmthera.2022.108328

  • The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials

    Author: Peng, Jia; Yang, Shucai; Ng, Calvin S. H.; Chen, George G.

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 241, Issue , pp. -. DOI: 10.1016/j.pharmthera.2022.108333

  • A natural products solution to diabetic nephropathy therapy

    Author: Hu, Qichao; Jiang, Lan; Yan, Qi; Zeng, Jinhao; Ma, Xiao; Zhao, Yanling

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 241, Issue , pp. -. DOI: 10.1016/j.pharmthera.2022.108314

  • Anticancer or carcinogenic? The role of estrogen receptor beta in breast cancer progression

    Author: Shen, Kang; Yu, Huiguang; Xie, Baohua; Meng, Qiuyu; Dong, Chune; Shen, Kun; Zhou, Hai-Bing

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 242, Issue , pp. -. DOI: 10.1016/j.pharmthera.2023.108350

  • Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets

    Author: Yang, Liu; Hao, Yawen; Boeckmans, Joost; Rodrigues, Robim M.; He, Yong

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 243, Issue , pp. -. DOI: 10.1016/j.pharmthera.2023.108353

  • BET proteins: Biological functions and therapeutic interventions

    Author: Guo, Jiawei; Zheng, Qingquan; Peng, Yong

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 243, Issue , pp. -. DOI: 10.1016/j.pharmthera.2023.108354

  • Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

    Author: Zhu, Huanjie; Wang, Jin; Zhang, Qingqing; Pan, Xiaoyan; Zhang, Jie

    Journal: PHARMACOLOGY & THERAPEUTICS. 2023; Vol. 244, Issue , pp. -. DOI: 10.1016/j.pharmthera.2023.108371